Moreover, from a clinical point of view, understanding whether the addition of ECM3 to the immune signatures increases the selection of patients who benefit from trastuzumab could represent an important issue for patient selection in the clinical practice.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}